title: Metabolic profile of antipsychotic-naive individuals with non-affective psychosis.
abstract: BACKGROUND
  Some studies suggest individuals with schizophrenia have an increased risk of diabetes prior to antipsychotic use. Small sample sizes and the potential for confounding by hypercortisolaemia have decreased confidence in those results.
  
  
  OBJECTIVE
  To examine diabetes-related factors in newly diagnosed, antipsychotic-naive people with non-affective psychosis.
  
  
  METHODS
  Participants with psychosis (the psychosis group; n = 50) and matched controls (the control group; n = 50) were given a 2 h oral glucose tolerance test. Fasting concentrations were also determined for adiponectin, interleukin-6 and C-reactive protein.
  
  
  RESULTS
  Compared with the control group, the psychosis group had significant increases in 2 h glucose and interleukin-6 concentrations, and in the prevalence of abnormal glucose tolerance (16% of psychosis group v. 0% of control group). Adiponectin and C-reactive protein concentrations did not differ significantly between the two groups. These findings could not be attributed to differences in cortisol concentrations, smoking, gender, neighbourhood of residence, body mass index, aerobic conditioning, ethnicity, socioeconomic status or age.
  
  
  CONCLUSIONS
  Individuals with non-affective psychosis appear to have an increased prevalence of abnormal glucose tolerance prior to antipsychotic treatment, as well as abnormalities in a related inflammatory molecule. These underlying problems may contribute to the metabolic side-effects of antipsychotic medications.
authors.affiliation: Schizophrenia Program, Department of Psychiatry, Neuroscience Institute, Hospital Clinic, Barcelona, Spain.
authors.forename: Emilio
authors.initials: E
authors.lastname: Fernandez-Egea
authors.forename: Miguel
authors.initials: M
authors.lastname: Bernardo
authors.forename: Thomas
authors.initials: T
authors.lastname: Donner
authors.forename: Ignacio
authors.initials: I
authors.lastname: Conget
authors.forename: Eduard
authors.initials: E
authors.lastname: Parellada
authors.forename: Azucena
authors.initials: A
authors.lastname: Justicia
authors.forename: Enric
authors.initials: E
authors.lastname: Esmatjes
authors.forename: Clemente
authors.initials: C
authors.lastname: Garcia-Rizo
authors.forename: Brian
authors.initials: B
authors.lastname: Kirkpatrick
mesh_terms: D052242:Adiponectin / Q000097:blood; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D044882:Glucose Metabolism Disorders / Q000453:epidemiology* / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D012559:Schizophrenia / Q000453:epidemiology / Q000378:metabolism*; D055815:Young Adult
chemical_list: D052242:Adiponectin; D014150:Antipsychotic Agents; D001786:Blood Glucose; D036341:Intercellular Signaling Peptides and Proteins; D015850:Interleukin-6; D002097:C-Reactive Protein